

**Amantadine, Oseltamivir and Zanamivir for the treatment of influenza
(review of Technology Appraisal 58)**

**Additional scenario analyses carried out by the Assessment Group for
FAD meeting**

The additional analyses have been performed in response to a request by NICE following consultation on the Appraisal Consultation Document (ACD). These analyses were performed on 20th October 2008.

Incremental cost effectiveness ratios (ICERs) were calculated for healthy populations to investigate the combined effect of:

- increases in GP consultations
- decreases in the probability that an influenza-like illness is true influenza
- exclusion of hospitalisation and mortality benefits
- a quality of life decrement of 0.2

	Healthy children ICER (£)	Healthy adults ICER (£)
<ul style="list-style-type: none"> • 5% increase in GP consultations • 5% decrease in the probability that ILI is influenza 	21,002.78	39,862.02
<ul style="list-style-type: none"> • 15% increase in GP consultations • 15% decrease in the probability that ILI is influenza 	31,490.55	65,606.54

Note: all scenarios exclude hospitalisation and mortality benefits and all scenarios have a quality of life decrement of 0.2